# Phase III/Seroquel SR Bipolar Depression Monotherapy - US

> **NCT00422214** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 400 (—)

## Conditions studied

- Affective Psychosis, Bipolar
- Depression, Bipolar
- Manic-Depressive Psychosis
- Psychoses, Manic-Depressive

## Interventions

- **DRUG:** Quetiapine fumarate (Seroquel) SR

## Key facts

- **NCT ID:** NCT00422214
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 400 (—)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422214, "Phase III/Seroquel SR Bipolar Depression Monotherapy - US". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00422214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*